Entero Healthcare Share Price Momentum After 3P Fund Stake And Q1 Revenue Growth
Key Takeaways
- 3P India Equity Fund acquired 10.88 lakh Entero Healthcare shares for Rs 104.99 crore at Rs 1,377.8 per share.
- The stake expands 3P's exposure to 2.5% of Entero's paid-up equity; Surbhi Singh holds 10.45% via Prasid Uno Family Trust as of June 2026 (45.5 lakh shares).
- Entero Healthcare Q1 revenue rose 38% YoY to Rs 1,940.5 crore; EBITDA stood at Rs 97 crore with EBITDA margin at 5%.
- Entero Healthcare stock has gained about 21% in the last month, 32% year-to-date, and roughly 50% over six months.
Entero Healthcare Share Price moved into the spotlight after 3P India Equity Fund acquired 10.88 lakh shares for Rs 104.99 crore, at Rs 1,377.8 apiece, expanding the company’s paid-up equity by 2.5%.
Surbhi Singh, through Prasid Uno Family Trust, held a 10.45% stake, equivalent to 45.5 lakh shares, in Entero Healthcare as of the June 2026 shareholding pattern. This shift sits in a broader growth narrative where Entero's MedTech ambitions align with the sizable, high-growth IVD and Cardiology/Orthopaedic devices segments.
Entero Healthcare Share Price Momentum After 3P Fund Acquisition
The 3P stake is a material signal that Entero Healthcare Stock could react to, especially as the market digests the Rs 104.99 crore investment and the 2.5% expansion in paid-up equity. The purchase price of Rs 1,377.8 per share and the 10.88 lakh share quantity translate into a visible inflection point for liquidity and market perception on the Entero Healthcare NSE. Investors should watch how this stake aligns with Entero’s existing distribution strengths and MedTech growth trajectory, including the synergies that come with the pharma distribution footprint.
Entero Healthcare Revenue Growth And Q1 Performance
Entero Healthcare reported consolidated revenue of Rs 1,940.5 crore for the quarter ended June 30, 2026, up 38% year-on-year from Rs 1,403.8 crore in the year-ago period. Consolidated PAT rose 72% YoY to Rs 52.1 crore, while PBT increased 85% to Rs 67.1 crore. Profit attributable to owners rose 37% YoY to Rs 38.2 crore. EBITDA surged 94% YoY to Rs 97 crore, with EBITDA margin expanding to 5% from 3.6% in the prior-year quarter.
Entero said its MedTech strategy targets large, high-growth segments, including IVD and Cardiology/Orthopaedic devices, with synergies to its existing pharmaceutical distribution business and potential consolidation opportunities in the space. This is the core strategic rationale behind the MedTech acquisitions and the ongoing focus on high-value distributors.
MedTech Growth Potential And Acquisition Strategy For Entero Healthcare
The MedTech opportunity is sizable and growing, and Entero believes there are meaningful consolidation opportunities as distributors in the MedTech ecosystem can deliver higher margins and value-add services than traditional pharmaceutical distributors. The firm’s emphasis on IVD and Cardiology/Orthopaedic devices aligns with a broad market trend toward high-growth diagnostics and surgical segments. By combining distribution scale with targeted device acquisitions, Entero aims to create a robust platform for margin expansion and faster revenue growth.
Entero Healthcare Stock Performance And Market Sentiment
Entero Healthcare’s stock performance has been robust over the last several months: around 21% gain over the past month, about 32% higher year-to-date, and roughly 50% higher over the last six months. This momentum reflects a combination of improving operating performance and investor interest in MedTech distribution plays.
What Retail Investors Should Watch Next And Actionable Steps
Retail investors should monitor the company’s upcoming quarterly results, especially the trajectory of MedTech devices and the performance of the IVD and Cardiology/Orthopaedic segments, to validate the sustainability of the revenue growth and margin expansion. It is also prudent to watch how the market prices Entero Healthcare’s expanding stake and potential further distributions or acquisitions. For deeper stock analysis and AI-driven insights, explore Swastika's Sarthi AI stock assistant: Swastika's Sarthi AI stock assistant.
Frequently Asked Questions
What are the key details of the 3P India Equity Fund's stake in Entero Healthcare?
The 3P India Equity Fund and related schemes bought 10.88 lakh Entero Healthcare shares for Rs 104.99 crore at Rs 1,377.8 per share, representing 2.5% of the company's paid-up equity.
What were Entero Healthcare's Q1 results?
For the quarter ended June 30, 2026, Entero Healthcare reported revenue of Rs 1,940.5 crore, up 38% YoY; PAT Rs 52.1 crore; PBT Rs 67.1 crore; PAT attributable to owners Rs 38.2 crore; EBITDA Rs 97 crore with an EBITDA margin of 5%.
How has Entero Healthcare stock performed recently?
The stock has risen about 21% in the last month, around 32% year-to-date, and roughly 50% over the last six months.
What is the significance of the 2.5% stake for Entero Healthcare and who holds a major stake side?
The 2.5% stake corresponds to 10.88 lakh shares acquired by 3P India Equity Fund for Rs 104.99 crore. Surbhi Singh, via Prasid Uno Family Trust, held 10.45% (45.5 lakh shares) as of June 2026.
What are Entero Healthcare's MedTech growth drivers?
Entero's MedTech strategy focuses on IVD and Cardiology/Orthopaedic devices, with synergies to its existing pharmaceutical distribution business and potential consolidation opportunities in the MedTech distribution space.
Conclusion
The Entero Healthcare share price is responding to a clear signal: a strategic stake infusion coupled with stronger quarterly results strengthens the growth narrative in MedTech. Retail investors should translate these signals into a plan–track next-quarter performance, evaluate how MedTech verticals scale, and apply a disciplined approach to valuation and risk. A practical mental model is to treat the stock as a Scaled Growth Play: monitor revenue efficiency, margin expansion, and the pace of device-market penetration while watching for any additional strategic moves.
Open your trading and demat account here
Reference :
1 : Economictimes
